



MEMORANDUM

Date: May 26, 2023

To: Marios Georgakis

From: Lindsey Bull
P&P Committee Coordinator

Subject: Manuscript 4789 – Carriers of rare damaging CCR2 genetic variants are at lower risk of atherosclerotic disease

Congratulations! The Publications and Presentations (P&P) Committee has approved this paper. Please see the reviews at the end of this memo for details.

You may now submit your manuscript for publication. It is important to keep WHI updated of your manuscript's status on an ongoing basis. Please notify P&P when your manuscript is submitted to a journal and accepted for publication by e-mailing (p&p@whi.org). As they become available, please send (1) a copy of the manuscript as accepted by the journal, (2) the published manuscript in PDF form, and (3) the NIH Manuscript Submission number/PubMed Central number. Authors are required to submit their published manuscript to PubMed Central; see <http://publicaccess.nih.gov> if you are unfamiliar with the NIH Public Access Policy.

Please be aware that lead authors are responsible for identifying and reporting any conflicts of interest among co-authors and noting these in the final manuscript, per journal requirements. Please ensure that all authors complete and report their conflicts on this paper. In addition, please be sure to keep all co-authors informed of your manuscript's progress. If a journal requires revisions, please solicit and incorporate co-author input and inform the P&P Chairs of any major disagreements among the writing group.

Please be reminded that, in accordance with the data use agreement you signed to obtain WHI data for this paper, the data may only be used for this approved analysis and may not be shared with anyone without authorization from WHI.

WHI Policy requires papers to be published with an appendix acknowledging WHI Investigators; please use the “short” list of WHI investigators that is available online at <https://www-whi-org.s3.us-west-2.amazonaws.com/wp-content/uploads/WHI-Investigator-Short-List.pdf>. All WHI publications must also include an acknowledgement that approximates the following: “The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005.” We also request that you consult www.whi.org for exact wording if you include a description of the WHI trials in your manuscript.

Review 1:

Comments:

This is a well-written manuscript summarizing findings from a comprehensive analysis on CCR2 variation and measures of atherosclerotic CVD that offers intriguing insight on the molecular aspect of atherogenesis and subsequent clinical sequelae. Best wishes with success during journal peer-review.

Review 2:

Comments:

I am not an expert in atherosclerotic disease but the manuscript is well-written and methods appear appropriate.